Latest News & Features
Europe
Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect. 28 March 2023
Big Pharma
NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says. 23 March 2023
Big Pharma
Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’. 23 March 2023
Big Pharma
As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates. 21 March 2023
Big Pharma
Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030. 21 March 2023
Biotechnology
New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing. 16 March 2023
Medtech
Dispute relates to AstraZeneca ‘Breztri’ brand | Court says no likelihood of confusion with earlier marks | Full details of reasoning. 16 March 2023
Americas
Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning. 14 March 2023
Biotechnology
“Customer suit exception” is rejected by district judge | Suit between Chr. Hansen and Glycosyn is ongoing. 14 March 2023
Biotechnology
The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process. 9 March 2023